Colorado Center for AIDS Research

Developing a collaborative research agenda for pharmacokinetics of HIV-related tuberculosis – a meeting of the AIDS Clinical Trials Group (ACTG) and Tuberculosis Trials Group (TBTC)

Held 28 August 2007, Denver, CO, open original agenda.

Conference organizers

• Sue Swindells, University of Nebraska and Chair of the OpMan Committee of the ACTG
• Diane Havlir, University of California – San Francisco, ACTG
• Bill Burman, University of Colorado and Chair, Core Science Group of the TBTC
• Amy Livingston, Colorado CFAR

Brief summary

Tuberculosis has been declared a global health emergency; the combined effects of HIV-co-infection and multidrug-resistant TB (MDR-TB) threaten global TB control. Thus, this is a time of unprecedented need for new TB drugs and research on TB therapeutics. Fortunately, this is also a time of unprecedented opportunity – 5 new drugs for TB have entered clinical trials, 3 of them in novel classes that retain full activity against MDR-TB and extremely drug-resistant TB (XDR-TB). Recognizing the urgent need for research on the pharmacokinetics and drug-drug interactions involving these drugs, particularly among patients with HIV co-infection, investigators from two large clinical trials groups, the AIDS Clinical Trials Group (ACTG) and Tuberculosis Trials Group (TBTC) met in Denver on August 28, 2007.

Presentations

Presenter	Topic
Overview of the ACTG	Constance Benson
Overview of the TBTC	Bill Burman
Pharmacokinetics research in the ACTG	Charles Flexner
Pharmacokinetics research in the TBTC	Marc Weiner
Global perspectives on HIV-TB PK priorities	Diane Havlir
Which drugs do we need to learn more about – interactions, PK/PD – and how might we do it?	Bill Burman
Pharmacogenomics	Courtney Fletcher

After these presentations, the group identified 4 key areas for collaborative efforts to move forward the research agenda for TB drug development among patients with HIV co-infection.